---
document_datetime: 2025-11-14 11:15:37
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/epruvy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: epruvy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.254309
conversion_datetime: 2025-12-24 16:15:41.909693
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Epruvy

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 13/11/2025                          |                                             | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                        |            | Labelling and PL   | EMA/VR/0000296796   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------|---------------------|
| Variation type IA / EMA/VR/0000303425 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted | 21/10/2025 |                    |                     |
| Variation type IB / EMA/VR/0000264588 | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted                                                                                             | 05/06/2025 | SmPC               |                     |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |                                  |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|
| Variation type IA / EMA/VR/0000246812 | This was an application for a group of variations. A.2 Change in the (invented) name of the medicinal product - A.2.a) for Centrally Authorised products - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality | 06/02/2025 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| for which the manufacturer/importer is responsible do not include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.a Tightening of in- process limits - Accepted   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|